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Signal peptide peptidase-likeSignal peptide peptidase (SPP) and the homologous SPP-like (SPPL) proteases SPPL2a, SPPL2b, SPPL2c and
SPPL3 belong to the family of GxGD intramembrane proteases. SPP/SPPLs selectively cleave transmembrane
domains in type II orientation and do not require additional co-factors for proteolytic activity. Orthologues of
SPP and SPPLs have been identiﬁed in other vertebrates, plants, and eukaryotes. In line with their diverse
subcellular localisations ranging from the ER (SPP, SPPL2c), the Golgi (SPPL3), the plasma membrane
(SPPL2b) to lysosomes/late endosomes (SPPL2a), the different members of the SPP/SPPL family seem to
exhibit distinct functions. Here, we review the substrates of these proteases identiﬁed to date as well as
the current state of knowledge about the physiological implications of these proteolytic events as deduced
from in vivo studies. Furthermore, the present knowledge on the structure of intramembrane proteases of
the SPP/SPPL family, their cleavage mechanism and their substrate requirements are summarised. This article
is part of a Special Issue entitled: Intramembrane Proteases.
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Signal peptide peptidase (SPP) and its homologues, the signal pep-
tide peptidase-like proteases (SPPLs) are aspartyl intramembrane-
cleaving proteases (I-CLiPs). SPP and SPPLs are closely related to
presenilins, which form the active subunit of the γ-secretase complex.
Together with the more distantly related bacterial type IV prepilin
peptidases (TFPPs) and their archaeal homologues, the pre-ﬂagellin
peptidases (PFPs), they constitute the GxGD protease family of I-CLiPs
(Fig. 1). All members of this family share a conserved GxGDmotif within
2829M. Voss et al. / Biochimica et Biophysica Acta 1828 (2013) 2828–2839their catalytic centre [1–4]. GxGD proteases have turned out to be part
of a fundamental sequential proteolytic processing pathway of single
span transmembrane proteins, termed regulated intramembrane prote-
olysis (RIP) [5] (Fig. 2). While a genetic link between the γ-secretase
complex and familial cases of Alzheimer's disease is well-documented
for two decades already, the SPP/SPPL family has only recently been
identiﬁed [4,6,7] and their likely diverse physiological functions have
not yet been completely unravelled. The aim of this review is to give
an overview of the biological diversity of SPP/SPPLs and to summarise
our current knowledge of the mechanistic principles applied by this
fascinating protease family.
2. The SPP/SPPL family
In 2002, SPP/SPPLs were ﬁrst described independently by three
groups [4,6,7]. Using bioinformatic analyses Ponting et al. and
Grigorenko et al. identiﬁed a family of ﬁve protein-coding genes with
homology to presenilins in the human genome [6,7]. At the same
time a biochemical approach sought to identify the enzyme responsible
for signal peptide cleavage leading to the identiﬁcation of SPP and its
homologues [4]. A proteolytic activity cleaving within signal peptide
sequences following their liberation from nascent proteins by signal
peptidase (Fig. 2B) had been observed before in vitro, for instance for
the prolactin signal sequence [8,9]. Subsequently, a peptide-based
inhibitor, 1,3-di-(N-carboxybenzoyl-L-leucyl-L-leucyl) amino acetone
((Z-LL)2 ketone), was described to target this proteolytic activity and
to inhibit signal peptide processing [10]. Using a photocrosslinkable
derivative of (Z-LL)2 ketone, Weihofen et al. were able to attribute
this proteolytic activity to an at that time uncharacterised human
multi-pass transmembrane protein. Sequence analysis revealed its
relationship to the presenilins and uncovered the homologous SPPLs
(Fig. 3) [4].
SPP/SPPLs are highly conserved and can be found in eukaryotes,
including fungi, protozoa, plants, and animals, highlighting their phys-
iological importance [4,6,7]. Interestingly, the number and nature of
SPP/SPPL paralogues differs among these organisms suggesting that
they have evolved diverse functions. While in mammals ﬁve members
(SPP, SPPL2a, SPPL2b, SPPL2c, and SPPL3) of the SPP/SPPL family have
been described (Fig. 3) [11], in zebraﬁsh, for instance, only one repre-
sentative of the SPPL2 subfamily is found [12]. Drosophila species
possess only two SPPLs, one most closely related to human SPP [13]
and the other to human SPPL3 [14] and the genome of Plasmodiumγ-secretase complex
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Fig. 1. Overview of the GxGD protease family. Members of the GxGD protease family includ
SPP), (B), the bacterial type 4 prepilin peptidases (exempliﬁed by Vibrio cholerae TcpJ), (C),
(D). Active site motifs are shown in violet, catalytic Asp residues in bold. Presenilins are
N-terminal fragment (NTF) and C-terminal fragment (CTF) and associate with Aph-1, Nic
extracellular space is shaded in blue, while cytosol is shown in orange.falciparum even solely encodes a single family member, an orthologue
of human SPP [15]. In contrast, plants, like the monocot Arabidopsis
thaliana or the dicot rice (Oryza sativa), encode a more complex set
of SPP/SPPLs [16].
Phylogenetic analysis of SPP/SPPLs in various species reveals that
most of them group with human SPP/SPPL family members (Fig. 4).
Notable exceptions include Caenorhabditis elegans and Saccharomyces
cerevisiae, respectively. C. elegans encodes ﬁve SPP/SPPL family
members, termed imp [17]. Imp-2 is an orthologue of human SPP
[17]. Imp-1a, imp-1b and imp-1c differ only slightly and, like imp-3,
are merely distantly related to mammalian and plant SPP/SPPLs.
Like imp-1 and imp-3, YKL100c, the SPP/SPPL homologue in
S. cerevisiae, does not clearly group with other SPP orthologues
(Fig. 4). In line with this, no proteolytic activity on substrates based
on human signal peptides was observed in yeast [4] and YKL100c
deﬁcient yeast was reported to be phenotypically normal [18]. This
suggests that the C. elegans and yeast SPP/SPPL homologues might
have physiological functions distinct from those of the vertebrate
SPP/SPPLs. Interestingly, plants share orthologues for animal SPP
and SPPL3 [16,19]. In contrast, orthologues of human SPPL2a/b/c are
only found in vertebrates [7], while plant SPPLs that exhibit no obvi-
ous relationship to animal SPP and SPPL3 form a distinct subfamily
which is merely distantly related to vertebrate SPPL2 proteases
(Fig. 4) [16]. Bacteria do not possess proteins exhibiting marked
homology to mammalian SPP or SPPLs. In bacteria, however, signal
peptide cleavage does occur but has been attributed to proteases
like SppA [20] or RseP [21], which are both completely unrelated to
SPP/SPPL GxGD proteases.
In contrast to bacteria, Archaeal genomes harbour in addition to
the aforementioned PFPs other putative GxGD proteases, like
Archaeoglobus fulgidus AF1952 [6] and many others [22], which are
clearly related to presenilins and/or SPP/SPPLs. Presently, however,
they cannot be clearly classiﬁed into either the SPP/SPPL or the
presenilin subfamily as for instance their topological orientation re-
quires experimental veriﬁcation, Hence, it is tempting to speculate
that these archaeal proteases may constitute a common ancestor of
the two families of eukaryotic GxGD proteases.
3. Physiological functions of SPP/SPPLs
There is accumulating evidence that all known SPP/SPPL proteins
are active intramembrane-cleaving aspartyl proteases as they areYD
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Fig. 2. Regulated intramembrane proteolysis (RIP) by SPP/SPPLs. (A) TNFα as prototyp-
ic type II RIP substrate. In an initial step, the ectodomain moiety of the substrate is lib-
erated by membrane-proximal shedding which is usually mediated by members of the
ADAM family. This generates a N-terminal fragment (NTF). Intramembrane cleavage
of the NTF by SPPL2a and/or SPPL2b releases secreted C-peptides and cytosolic ICDs.
(B) Cleavage of signal peptides by SPP in the ER membrane. Following synthesis at
the ER membrane, nascent secretory proteins are translocated into the ER lumen
through the translocon (yellow) and signal peptides are removed by signal peptidase.
Subsequently, signal peptides are cleaved by SPP within the lipid bilayer and
the respective signal peptide fragments are released from the ER membrane.
(C) Intramembrane cleavage of type III membrane proteins by SPPLs, exempliﬁed by
foamy virus envelope protein (FVenv). The type III membrane protein is initially
cleaved by SPPL3 or other proteases (e.g. proprotein convertases, not depicted) to gen-
erate a NTF and the membrane anchored counterpart. The NTF is subsequently cleaved
by SPPL2a/b to liberate C-Peptides and ICDs. The luminal/extracellular space is shaded
in blue, while cytosol is shown in orange.
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Fig. 3. Overview of human SPP/SPPL family members. In humans the SPP/SPPL family
includes SPP (A), SPPL3 (B), SPPL2a (C), SPPL2b (D), and SPPL2c (E). Members are
shown schematically and their respective YD, GxGD, and PAL motifs are highlighted
(violet). The catalytically active aspartyl residues are highlighted in bold and their
respective position is indicated. SPPL2a, SPPL2b, and SPPL2c are synthesised as
pre-proteins and their signal sequences (yellow) are removed, presumably by signal
peptidase. Putative signal peptidase cleavage sites (black arrowhead) are indicated
according to predictions in UniProt. Consensus N-glycosylation sites for human SPP
(N10, N20), human SPPL2a (N58, N66, N74, N116, N126, N149, N155), human
SPPL2b (N97, N129, N403), and human SPPL2c (N100) are indicated. Two SPPL2b
isoforms have been documented in mammals that differ in the length of their
C-terminal cytosolic tails (aa 512 or 592, shaded). Signals ensuring proper subcellular
localisation to the ER and the endosomal/lysosomal compartment for SPP and SPPL2a,
respectively are indicated. The luminal/extracellular space is shaded in blue, while
cytosol is shown in orange.
2830 M. Voss et al. / Biochimica et Biophysica Acta 1828 (2013) 2828–2839either inhibited by transition state analogue inhibitors or their activ-
ity is impaired upon mutagenesis of the catalytic aspartate residues
[4,23–25]. However, non-catalytic physiological functions of these
proteins cannot be excluded at the present time. In addition, for
various enzyme classes inactive pseudoenzymes have been observed.
Such pseudoenzymes may have evolved very important physiologicalfunctions that might rely on properties they share with their active
relatives, as exempliﬁed by the transmembrane domain (TMD)-
binding capacity of inactive rhomboid pseudoproteases (discussed
in [26]). So far, however, SPP/SPPL family members lacking the intact
active site motifs have not been identiﬁed.
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SPP, the founding member of the family, is actively retained in the
endoplasmic reticulum (ER) due to its KKXX retention signal in ani-
mals [12,24,27]. Interestingly, a splice isoform of SPP found in miceTable 1
Substrates identiﬁed for SPP/SPPL proteases. Substrates identiﬁed for the respective
SPP family in vitro or in a cellular setting. For SPPL2c no substrates have been reported
so far. For non-human substrate proteins the respective species is given in parentheses.
*, FVenv is synthesised as a type III transmembrane protein precursor and its
N-terminal TMD is in type II orientation. SPPL2b cleaves this TMD only following a
membrane-proximal pre-cleavage (i.e. a type II protein fragment), while SPPL3 can
cleave FVenv full length (i.e. the type III holoprotein).
Protease Substrate type Substrate Reference
SPP Signal peptide Prolactin (bovine) [10,122]
HIV gp160 (viral) [10,122]
MHC class I (HLA-A*0301) [34]
Calreticulin (rat) [69]
VSV G (viral) [69]
Crumbs (Drosophila) [30]
Pro-calcitonin [33]
Eosinophil cationic protein [31]
Multipass proteins IgSF1 [42]
HCV polyprotein (viral) [43]
Retrotranslocation MHC class I [52]
SPPL2a Type II protein TNFα [23,24]
Bri2 [25]
FasL [60]
CD74 (murine) [61–63]
FVenv [70]
SPPL2b Type II protein TNFα [23,24]
Bri2 [25]
Transferrin receptor 1 [123]
Type III protein* FVenv (viral) [70]
SPPL3 Type III protein* FVenv (viral) [70]lacks the retention signal and is accordingly observed at the plasma
membrane [28]. In plants, SPPs likewise localise to the ER [16,19],
but Arabidopsis SPP lacks a conventional retention signal. Similarly,
Plasmodium SPP also was observed to localise to the ER throughout
the parasite life cycle [18,29]. SPP appears to have evolved very
diverse functions and was initially identiﬁed due to its capability to
cleave signal peptides in vitro and in cellular model systems.
Substrates described so far are listed in Table 1. In some cases,
SPP-mediated intramembrane cleavage of signal peptides facilitates
their removal from the ER membranes and subsequent degradation
[30] or leads to detoxiﬁcation [31]. Apart from that, signal peptides
and their SPP cleavage products may possess post-targeting functions
that possibly have crucial roles in diverse cellular processes [32]. In
particular, SPP activity is implicated in immunosurveillance by gener-
ating peptides presented on polymorphic MHC class I [33] and
non-polymorphic HLA-E molecules [34]. Interestingly, a number of
antigenic MHC-presented peptides have been shown to originate
from signal peptide sequences of pre-proteins [35]. In principle,
intramembrane cleavage of such signal peptides within their
membrane-spanning segment could lead to the release of antigenic
fragments into the cytosol and/or the ER lumen, allowing for trans-
porter associated with antigen presentation (TAP)-dependent and
TAP-independent MHC class I loading, respectively (discussed in
[36]). Lemberg et al. initially reported (Z-LL)2 ketone-dependent
cleavage of HLA-A*0301 signal peptides in vitro and showed that
SPP-mediated processing of HLA-A*0301 to nonamer peptides and
TAP-dependent transport thereof was required for surface presenta-
tion by HLA-E [34]. Likewise, HLA-E surface levels could be reduced
in cell culture following treatmentwith (Z-LL)2 ketone [37]. Proper sur-
face expression of HLA-E is thought to prevent cytotoxic action of nat-
ural killer cells, but so far the direct role of SPP in such a process has not
been proven in vivo. In addition to MHC signal peptides, another study
described a cytotoxic T cell clone obtained from tumour-inﬁltrating
lymphocytes of a human non-small-cell lung carcinoma which speciﬁ-
cally recognised the C-terminal portion of the calcitonin pre-protein
signal peptide [33]. Generation of this peptide in the tumour was
TAP-independent, yet required successive proteolytic cleavage of the
pre-protein by signal peptidase and SPP [33]. Interestingly, cells of
this tumour were later shown to display low levels of endogenous
TAP, which is frequently observed in lung cancers, and restoration of
TAP levels reduced presentation of the signal peptide-derived peptide,
probably due to competition with proteasome/TAP-dependently gen-
erated peptides [38]. Similar MHC class I-presented peptides derived
from signal sequences have already been observed earlier [35],
suggesting that in fact successive cleavage of signal peptides by signal
peptidase and SPP might constitute an alternative pathway applied to
generate peptides for MHC class I presentation.We therefore anticipate
that future work will identify additional immunogenic peptide frag-
ments generated by SPP activity from other protein substrates.
Other post-targeting functions of signal sequences are also well
established (reviewed in [32]). Interestingly, however, such post-
targeting functions of signal peptides not necessarily always depend on
SPP activity. Fragments may be released by alternative mechanisms as
exempliﬁed by the mouse mammary tumour virus protein Rem which
is released frommembranes in a (Z-LL)2 ketone-insensitivemanner [39].
Notably, in vitro cleavage of SPP model substrates based on verte-
brate signal peptides is not restricted to human SPP, but has also
been shown for SPPs from other distinct species, like Drosophila
melanogaster, suggesting that the signal peptide degrading activity
of SPPs is conserved among species [13,40]. In the plant Medicago
truncatula, SPP was observed to be co-regulated with a family of
nodule-speciﬁc secretory proteins [41] suggesting that either also
plant SPP could be functionally linked to signal peptide processing
or that it can affect secretion by an alternative mechanism not yet un-
derstood. Further studies are required to address whether processing
and turnover of signal peptides is conserved throughout species.
2832 M. Voss et al. / Biochimica et Biophysica Acta 1828 (2013) 2828–2839In addition to the processing of classical N-terminal signal
peptides, SPP may also cleave within internal membrane-spanning
sequences. One such example is the immunoglobulin-like protein
IgSF1 which is cleaved within an internal stop transfer sequence in
the ER membrane by signal peptidase and subsequently by a (Z-LL)2
ketone-sensitive protease, most likely SPP [42]. Similarly, the
N-terminal core domain of hepatitis C virus (HCV) and related mem-
bers of the Flaviridae is initially proteolytically released from the re-
spective polyprotein and cleaved by signal peptidase and SPP within
a hydrophobic internal stretch [43–45]. This cleavage is required
for efﬁcient virus propagation [46–48], suggesting inhibition of SPP-
mediated HCV core cleavage as a putative therapeutic approach
in HCV infections. In addition, the SPP orthologue expressed in
P. falciparum is considered a promising target for treatment of malar-
ia, since pharmacological interference with SPP proteolytic activity
using (Z-LL)2 ketone, cross-reactive γ-secretase inhibitors, or newly
developed potent SPP inhibitors severely inhibits Plasmodium growth
[15,18,29,49,50]. Treatment with SPP inhibitors is also toxic to other
protozoan species, suggesting that SPP could constitute a pan-
protozoan drug target [18]. However, data on a potential inhibition
of SPP-mediated Plasmodium invasiveness remains controversial
[29,50] (reviewed by Sibley [51] 2013-in this issue).
While all the above-mentioned observations clearly rely on its
proteolytic function, SPP has also been linked to dislocation of mem-
brane proteins from the ER. For example, the human cytomegalovirus
(HCMV) protein US2, a viral immunoevasin that targets MHC class I
molecules for proteasomal degradation by inducing their dislocation
from the ER membrane, associates with SPP [52]. In addition,
RNAi-mediated reduction of endogenous SPP levels led to a reduced
induction of US2-dependent MHC dislocation [52]. Protein disulﬁde
isomerase (PDI) was recently proposed to be involved in the US2
pathway of MHC dislocation and associated with SPP [53]. Similarly,
the E3 ubiquitin ligase TRC8 (translocation in renal carcinoma, chro-
mosome 8 gene) was identiﬁed in a RNAi screen as essential mediator
of US2-mediated MHC translocation and was also observed to form a
heteromeric complex with US2 and SPP [54]. The exact mechanism of
SPP-dependent pathway of MHC class I translocation has not been
fully unravelled yet. Often, viruses hijack host cellular pathways
suggesting that, in fact, SPP could be an integral part of a cellular
ER-associated degradation (ERAD) pathway. This notion is supported
by a recent integrative study mapping the human ERAD networks
[55]. In line with this, SPP was described to associate with misfolded
or misassembled membrane proteins in the ER [56,57]. A crucial
unresolved question is whether the role of SPP in ERAD relies on its
intrinsic activity as an aspartyl protease or is mediated independently
thereof. Recently, however, work on Plasmodium, which harbours
orthologues for only a few knownmammalian ERAD factors including
P. falciparum SPP (PfSPP), revealed that PfSPP-mediated ERAD is
targeted by small molecule inhibitors which interfere with its proteo-
lytic activity leading to Plasmodium lethality [18], suggesting that
indeed the role of SPP in ER retrotranslocation indeed relies on its
proteolytic activity. In order to unravel the precise role of SPP in
cellular ERAD pathways more detailed studies are required.
In addition, data from animal models suggest that SPP has an
essential function during development [12,13,17]. For instance,
dsRNA-induced reduction of imp-2, the SPP orthologue in C. elegans,
led to embryonic lethality and a molting deﬁcit. This phenotype mim-
icked abnormalities observed in other loss-of-function models of
genes involved in steroid homeostasis and signalling [17]. Similarly,
anti-sense-mediated SPP knockdown in zebraﬁsh resulted in devel-
opmental abnormalities and neuronal cell death [12]. Likewise, in
Drosophila, SPP deﬁcient larvae had abnormal tracheae and died
early [13]. The latter phenotype was rescued by exogenous addition
of active SPP but not by a catalytically inactive mutant, suggesting
that proteolytic activity is crucial for the SPP function in development
[13]. These observations implicate that SPP activity is strictly requiredfor eukaryotes and that SPP certainly has a very fundamental cellular
function and, hence, SPP deﬁciency is not tolerated. Currently,
however, the exact biochemical and cellular consequences of SPP
dysfunction are unknown and it is unclear whether they are related
to the putative roles of SPP in signal peptide processing, in ERAD
pathways, in both processes, or to so far unknown functions.
3.2. SPPL2a, SPPL2b, and SPPL2c
Unlike the other members of the SPP/SPPL family, the SPPL2
subfamily members comprise an N-terminal signal sequence and a
complexly glycosylated luminal/extracellular domain N-terminal of
the core nine-TMD segment common to all SPP/SPPLs (Fig. 3) [58].
SPPL2a and SPPL2b are synthesised at the endoplasmic reticulum
and then follow the secretory pathway. Exogenously expressed
human SPPL2a was observed in the endolysosomal compartment in
HEK293 cells [24]. Conﬁrming these results, endogenous SPPL2a
was recently described to reside in lysosomes/late endosomes of mu-
rine embryonic ﬁbroblasts and lysosomal sorting of SPPL2a critically
depends on a canonical C-terminal tyrosine-based sorting signal
which is not present in SPPL2b [59]. Upon overexpression in HeLa
cells, minor, but signiﬁcant amounts of SPPL2a were present at the
cell surface [59]. Further studies may be needed to systematically
analyse this under endogenous conditions in different cell types and tis-
sues and to assess any functional relevance. In contrast, overexpressed
SPPL2b was detected primarily at the cell surface [24,59], but also in
the Golgi [25] and to some extent in endolysosomal vesicles [12]. To
ﬁnally clarify the subcellular localisation of SPPL2b, studies on endoge-
nous SPPL2b need to be performed.
Overexpression or RNAi-mediated knock down of either SPPL2a or
SPPL2b in cell culture models demonstrates that both proteases are
able to cleave selected type II membrane proteins like for instance
TNFα [23,24] (Table 1 lists all SPPL2a and/or SPPL2b substrates
identiﬁed so far). Under the same conditions, however, Fas ligand
(FasL/CD95L), another member of the TNF superfamily, was reported
to be cleaved exclusively by SPPL2a [60]. Recently, the invariant chain
(li, CD74) of the MHC II complex was identiﬁed as a novel substrate of
murine SPPL2a [61–63]. It has not been investigated yet, if SPPL2b is
also able to proteolyse CD74. For all substrates of SPPL2a/b reported
to date (Table 1), the fate and putative biological function of the
resulting cleavage products is a central unresolved question.
SPPL2a-mediated intramembrane proteolysis of FasL liberates a FasL
intracellular domain (ICD), which bears SH3 domain binding sites
and was suggested to translocate to the nucleus [60]. There, it was
shown to inhibit lymphoid-enhancer binding factor-1 (Lef-1)-
dependent transactivation of transcription [64]. Using a knock-in
mouse model lacking the FasL ICD, the authors conclude that FasL
ICD signalling negatively regulates activation-induced proliferation
of B and T cells by diminishing phosphorylation of PLCγ, PKC
and ERK1/2 [64]. However, in order to deﬁne the precise role of the
FasL intramembrane cleavage in initiating or terminating these sig-
nalling pathways additional studies may be required. Similarly,
SPPL2a/b-mediated intramembrane proteolysis of TNFα in bone
marrow-derived dendritic cells was claimed to up-regulate transcrip-
tion and secretion of IL-12, a Th1 cytokine [24]. Whether TNFα ICD
translocates to the nucleus and directly activates transcription of
the IL-12 gene or whether this is due an indirect effect remains to
be shown. Furthermore, the in vivo relevance of this process is far
from clear. It may be anticipated that SPPL2a/b single and double de-
ﬁcient animals will help to clarify whether the IL-12 induction ob-
served in bone marrow-derived dendritic cells has a fundamental
role during the initiation of immune responses.
Recently, unambiguous in vivo relevance was demonstrated for the
SPPL2a-mediated intramembrane cleavage of CD74 [61–63]. The main
function of CD74 is to mediate assembly and subcellular targeting of
MHC class II complexes. In the peptide-loading compartments, the
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lymphocytes of SPPL2a-deﬁcient mice, the remaining membrane-
bound N-terminal fragment (NTF) of CD74 accumulates [61–63]. This
clearly highlights the absolute requirement of SPPL2a intramembrane
cleavage for the turnover of this NTF. At the subcellular level, the ap-
parently unphysiological amounts of this fragment signiﬁcantly disturb
membrane trafﬁcking within the endocytic system as documented by
massive ultrastructural changes [61]. Phenotypically, this manifests as
a distinct developmental arrest of splenic B cell maturation at the tran-
sitional stage T1 leading to a deﬁciency of mature B cells in these mice
in combination with signiﬁcantly impaired functionality of the residual
B cells [61–63]. A signiﬁcant amelioration of these phenotypes at the
cellular and subcellular level was observed by additional ablation of
CD74 in SPPL2a−/− CD74−/− mice [61,62]. This clearly identiﬁes a
causative role of the accumulating CD74 fragment and reveals the im-
portant role of SPPL2a for controlling the levels of this fragment by ini-
tiating its degradation. Based on these ﬁndings, pharmacological
inhibition of SPPL2a may represent a promising therapeutic approach
for depleting and/or modulating B cells for treating autoimmune disor-
ders. In addition, decreased numbers of CD8− dendritic cells were
observed in SPPL2a deﬁcient animals and were similarly restored
in SPPL2a−/− CD74−/− mice [62,63]. Interestingly, in vivo SPPL2a-
mediated intramembrane proteolysis also appears to be critical for
tooth enamel formation [66] but the exact molecular mechanisms
underlying this observed phenotype are presently unclear.
In addition, a genome-wide association study linked a single
nucleotide polymorphism on chromosome 15 close to the SPPL2a
locus to the inﬂammatory disorders psoriasis and psoriatic arthritis
[67]. In line with this, the authors also observed profound epidermal
SPPL2a expression in sections of lesional and unaffected skin, yet a
detailed characterisation of SPPLa's role in such skin disorders in
currently missing.
Taken together, this highlights the physiological role of SPPL2a
and SPPL2b within the hematopoietic system and for the regulation
of inﬂammatory responses. Nonetheless, based on its ubiquitous
expression [58], the list of hitherto identiﬁed SPPL2a/b substrates is
certainly not yet complete. Therefore, the role of these proteases in
other tissues needs to be addressed in future studies that certainly
will lead to the identiﬁcation of yet unknown substrates.
To date, the physiological function of SPPL2c is completely un-
known. In fact, given its highly polymorphic and intron-less structure,
the SPPL2C gene was discussed to be a recently evolved pseudogene
[68]. Moreover, SPPL2c fails to cleave all known SPPL2a/b substrates
when co-expressed in cellular model systems (Fluhrer et al.
unpublished data) and to date still no substrates have been described
that are selectively proteolysed by SPPL2c. Thus, although the active
site motives of GxGD aspartyl proteases are conserved within
SPPL2c [6,58], the ﬁnal proof that SPPL2c is indeed a catalytically
active member of the SPP/SPPL family is still missing.
3.3. SPPL3
SPPL3 is the smallest member of the SPPL family, is not glycosylated
and localises to the Golgi network [24]. Initial studies in cellular model
systems and in vitro described proteolytic activity of human SPPL3
towards a reporter construct [15]. The construct was based on the
membrane-spanning stretch of HCMV gpUL40 which only after muta-
genesis becomes a substrate for SPP [69]. In addition, the SPPL3
orthologue from D. melanogaster was shown to cleave a synthetic
peptide in vitro [40]. This peptide, in turn, was based on the bovine
pre-prolactin sequence, another known SPP substrate [10,69]. Based
on these observations, the high sequence homology, a very close evolu-
tionary relationship of SPP and SPPL3 (Fig. 4) and the ER localisation of
both proteases observed in an early study [12], it was suggested that
SPP and SPPL3 have a redundant physiological function in signal pep-
tide cleavage/degradation [12,15]. This notion, however, was recentlyheavily challenged, since catalytically inactive SPPL3 – in contrast to
the respective SPP mutant – failed to associate with signal peptide
substrates in a cellular model system [57]. Moreover, genomic ablation
of both D. melanogaster spp and the respective SPPL3 orthologue, sppL,
did not exacerbate the phenotype observed before in ﬂies solely
deﬁcient for SPP [14]. Recently, foamy virus envelope glycoprotein
(FVenv) was shown to be endoproteolysed by human SPPL3 in a cell
culture model system (Fig. 2C) [70].
Given its high evolutionary conservation in diverse organisms (see
Fig. 4) it is nonetheless tempting to assume that SPPL3 has an impor-
tant physiological function throughout these species, which still
remains enigmatic. Unexpectedly, however, in vivo studies with
SPPL3-deﬁcient Drosophila have so far not observed an overt pheno-
type [14]. Merely in the developing zebraﬁsh gripNA-mediated
knock-down of SPPL3 led to neuronal cell death [12]. In addition,
the D. melanogaster SPPL3 orthologue is widely expressed during
early developmental stages, while at later stages mRNA levels are
reduced [14], suggesting an important role during embryonic
development.
4. Mechanism of SPP/SPPL-mediated intramembrane proteolysis
4.1. Structure and topology of SPP/SPPLs
All SPP/SPPL family members are predicted to be multi-pass
membrane proteins with nine TMDs (Fig. 3). The nine TMD topology
has been anticipated from the homology to the presenilin family and
the luminal and cytosolic orientation of the N- and C-termini, respec-
tively, as well as the luminal orientation of the hydrophilic loop be-
tween TMD 6 and TMD 7 were conﬁrmed experimentally [58].
Strikingly, the overall topology of SPP/SPPLs is inverted compared to
presenilins (Fig. 1) [4,58,71]. Another distinction between SPP/SPPLs
and presenilins is that upon incorporation into the high molecular
weight complex presenilin is autoproteolytically cleaved [72] and
thus activated [73]. In contrast, no autoproteolytic cleavage required
for SPP/SPPL function has been observed so far. Due to the inverted
topology the corresponding loop domain in SPP/SPPLs is exposed to
the luminal/extracellular site [58,71]. In addition, it is comparably
short and lacks the hydrophobic amino acid sequence conserved in
presenilins. Therefore it is likely, that the loop between TMD 6 and
TMD 7 of SPP/SPPLs does not interfere with the catalytic centre and
thus activation of SPP/SPPLs through autoproteolysis is not necessary.
As in all known aspartyl ICLiPs, the two catalytic aspartic residues re-
quired for the proteolytic activity of SPP/SPPL proteases, are embedded
in conserved (Y/F)D and G(L/I/F)GD amino acid motifs in TMD6 and
TMD7, respectively (Fig. 3). Mutation of either aspartyl residue
inactivates the proteolytic activity of the respective SPP/SPPL
[4,23,24,60,70] but, in contrast to presenilins, exogenous expression
of such SPP/SPPL mutants does not affect the levels of the respective
endogenous proteases [25,73]. In addition to the amino acid motifs in
TMD 6 and TMD7 all SPP/SPPLs comprise a conserved QPALLY motif
in the N-terminal part of TMD 9 [4,6,7]. By the use of cysteine scanning
methods, a similar motif in TMD 9 of presenilin was shown to be locat-
ed close to the active site aspartic residue in TMD 6 [74,75]. Moreover,
mutation of the proline, alanine or leucine in either SPP or presenilin
signiﬁcantly affected the catalytic activity of the respective enzyme
[76–78], suggesting that this conserved motif is of crucial importance
for catalysis, substrate interaction, or active site architecture. Yet the
formal proof whether the QPALLY motif in TMD 9 of all other SPP/SPPL
family members also contributes to their catalytic activity is missing.
While presenilins strictly require three other proteins (anterior
pharynx defective 1(Aph-1), presenilin enhancer 2 (Pen-2), and
nicastrin) to form the proteolytically active γ-secretase complex
[73,79], exogenous expression of SPP/SPPLs in cellular model systems
strongly increases the processing of the respective substrates
[23,25,57,60,70]. This suggests either that SPP/SPPLs are proteolytically
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additional cellular co-factors needed for proteolytic activity of SPP/
SPPLs are highly abundant. Endogenous SPP from human cell lysates
and brain tissue has been detected as a SDS-resistant but heat-
sensitive dimer [12,80,81], which was speciﬁcally labelled by an active
site-directed photoafﬁnity probe, supporting the hypothesis that the
SPP dimer is catalytically active [80]. Fluorescence lifetime imaging mi-
croscopy of intact cells expressing two distinctly ﬂuorophore-labelled
species of human SPP also provides evidence that human SPP forms
homodimers [82]. These homodimers, however, were predominantly
observed close to the plasma membrane, whereas, under physiological
conditions, SPP is localised to the ER via a KKXX retention signal
(discussed above). More recently, however, analysis of SPP and
SPPL2b on native gels revealed species with a signiﬁcantly higher mo-
lecular weight than expected for the respective dimers [57,81]. The
molecular weight of these complexes suggests the formation
of homotetrameric complexes of SPP [81]. Interestingly, also the ar-
chaeal PSH was crystallised as a tetrameric protein [83]. Such SPP
homotetramers were also observed when human SPP was expressed
in insect cells. By afﬁnity puriﬁcation of these tetramers recently the
ﬁrst structural data on SPP at a resolution of 22 Å following 3D recon-
stitution of electron microscopic images of negatively stained SPP par-
ticles were obtained [81]. According to this, the SPP complex has four
low density interior regions as well as four concave regions which,
the authors hypothesize, could correspond to putative active and sub-
strate entry site, respectively [81]. Interestingly, it is claimed that the
C-terminus (i.e. TMD 6 to 9) of SPP harbours both the active as well
as the initial substrate binding site, since a recombinantly expressed
C-terminal fragment of SPP was sufﬁcient to cleave a model substrate
in DDM-solubilised E. colimembranes [40]. In line with this, the corre-
sponding N-terminal SPP fragment could neither be targeted with he-
lical peptides, known to bind the substrate “docking site”, nor with
transition state analogue inhibitors, known to bind to the active site
[81]. Nonetheless, the same N-terminal SPP fragment was able to
disrupt the assembly of the homotetrameric complex, implying that
the N-terminal region of SPP acts as internal scaffold to ensure
homotetrameric complex assembly and proteolytic activity of the
C-terminal core domain [81]. In addition, high molecular weight com-
plexes other than a putative homotetrameric SPP complex have been
described [57]. These complexes with a molecular weight two to
three times larger than that of the homotetrameric complex seem to
differ in regard to substrate binding and binding of misfolded/unfolded
proteins [57]. Recently, in a proteomic analysis of SPP binding partners,
vigilin, a cytoplasmic protein involved in RNA binding and protein
translation control, was found to interact with SPP in a high molecular
weight complex, yet it did not alter or affect proteolytic activity of SPP
[84]. This may indicate that SPP (and possibly SPPLs) forms highmolec-
ular weight complexes with additional binding partners that, though
they do not to affect proteolytic activity, contribute to possible
non-proteolytic functions of SPP/SPPLs. Whether these interactions
are dynamic and potentially regulated and whether they are cell
type-speciﬁc or dependent on special cellular conditions remains to
be investigated.
In order to obtain an in-depth biochemical and spatial under-
standing of the catalytic mechanisms applied by SPP/SPPLs the atomic
structures of the protease ideally with a substrate in a lipid environ-
ment is ultimately required. As this is a technically highly demanding
goal, atomic structures have neither been described for vertebrate
SPP/SPPLs nor for the obviously more complex multi-subunit
γ-secretase (reviewed by Wolfe [85] 2013-in this issue). Recently,
however, the ﬁrst atomic structures of archaeal GxGD proteases
have been reported [83,86]: Hu et al. obtained a crystal structure of
the PFP Flak (Fig. 1D) from Methanococcus maripaludis at 3.6 Å [86].
FlaK bears one aspartyl residue essential for catalytic activity in
TMD 1, a GxGD motif close to the helical segment of TMD 4, and a
proline-tipped, kinked TMD 6 which together form the threetransmembrane segments of the active site [86] suggesting they can
be compared to TMD 6, TMD 7, and TMD 9 which contribute to the
formation of the active site in presenilins (see the review by Wolfe
[85] 2013-in this issue). Since the primary structure of FlaK has only
a vague resemblance to SPP/SPPLs and presenilin it is questionable
at this point whether the results of this study can be fully transferred
to these proteases. More recently, in a landmark paper Li et al. pub-
lished the ﬁrst crystal structure of the Methanoculleus marisnigri
intramembrane protease JR1 [83]. Judged by its sequence homology
this protease can clearly be attributed to the presenilin/SPP/SPPL
type of GxGD proteases (see Section 1) [22] and is targeted by the
same type of active-site directed inhibitors [22,83]. Hence, it can be
considered a prototypic protease of this class. Like presenilins and
SPP/SPPLs it harbours nine transmembrane helices with TMD 6,
TMD 7, and TMD 9 containing the YD, GxGD, and the proline motif,
respectively, forming the putative active site [83]. Of note, however,
JR1 was crystallised in an obviously inactive conformation, as the dis-
tance observed between the active site aspartates would not support
catalysis. Therefore, the structure reported might not fully resemble
the active protease in a substrate-bound state. Given its evolutionary
relationship to presenilins and SPP/SPPLs (compare Fig. 4) and that
the structure obtained is mostly in line with biochemical data for
presenilins in the γ-secretase complex we can, however, assume
that SPP and SPPLs will structurally likely also adopt the presenilin
fold reported by Li et al. [83]. Nonetheless, structural studies on verte-
brate SPP/SPPLs are ultimately required to conﬁrm this notion.
4.2. Substrate requirements of SPP/SPPLs
While presenilins exclusively accept type I transmembrane sub-
strates [87], SPP/SPPLs seem to be selective towards transmembrane
substrates in type II orientation [4,58,71]. It is very likely, that the
inverted topology of the two protease families (Fig. 1A + B) causes
this strict speciﬁcity for either class of substrates [4,58,71]. The formal
proof for this hypothesis is, however, missing.
SPP/SPPLs are implicated in a two-step proteolytic process,
termed RIP (Fig. 2), which either liberates bioactive protein fragments
or domains from transmembrane proteins or facilitates the clearance
of protein fragments from cellular membranes and initiates their sub-
sequent degradation [11,87]. In an initial step the substrate is cleaved
within its luminal/extracellular domain to liberate the ectodomain
from single-pass transmembrane proteins or to cut a hairpin loop
between two TMDs of a multi-pass transmembrane protein. This
proteolytic process is termed “shedding” and generates an integral
membrane protein fragment with a rather short ectodomain (Fig. 2A).
These protein fragments are subsequently endoproteolysed within the
lipid bilayer by the respective intramembrane protease, causing the
release of ICDs into the cytosol and of C-peptides into the lumen/
extracellular space (Fig. 2A) [5].
Substrate shedding is a prerequisite for the subsequent intra-
membrane proteolysis and consequently the rate-limiting, regulative
step initiating this whole proteolytic cascade. In line with this,
endoproteolysis of signal peptides by SPP within their membrane-
spanning stretch strictly requires them to be removed from the nascent
protein by signal peptidase cleavage (Fig. 2B) [69]. Moreover, efﬁcient
intramembrane cleavage by SPPL2b requires substrates which have un-
dergone ectodomain shedding [70,88]. Consistently, TNFα [23,24], Bri2
[25], and FasL [60] require membrane-proximal ectodomain shedding
which is mediated by the family of A Disintegrin and Metalloproteases
(ADAMs) in order to be subsequently cleaved within their membrane-
spanning domains by SPPL2a/b. Similar requirements have been
known for substrates of presenilin [89]. The γ-secretase complex com-
ponent nicastrin, which is a single-span transmembrane protein with
a large and highly glycosylated ectodomain, was claimed to be responsi-
ble for the selectivity of presenilin towards transmembrane proteins
with a short ectodomain [90] though this notion has meanwhile been
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[4] they must have developed a protease-intrinsic mechanism to selec-
tively bind substrates that match the criteria described above. So far,
however, domains within SPP/SPPLs that mediate speciﬁc binding of
type II transmembrane substrates with an ectodomain shorter than 60
amino acids, have not been identiﬁed.
Unlike SPP, SPPL2a, and SPPL2b, which, according to the data pub-
lished so far, are strictly selective towards substrates with a short
ectodomain, SPPL3 was recently described to efﬁciently cleave its
substrate FVenv carrying a mutation that prevents pro-protein
convertase-mediated shedding of this viral protein [70]. Moreover,
cleavage of full-length FVenv by SPPL3 results in a membrane protein
fragment with a short ectodomain that is consecutively processed by
SPPL2a or SPPL2b (Fig. 2C) [70]. Hence, in this context SPPL3 acts as
sheddase initiating an alternative RIP cascade of FVenv [70]. The abil-
ity of I-CLiPs to cleave intact single-pass transmembrane proteins was
so far only attributed to members of the rhomboid family, which
belongs to the class of serine intramembrane proteases [92]. Since
no cellular substrates of SPPL3 have been described, it is not yet
known whether SPPL3 also cleaves full-length substrates in a physio-
logical context. Nonetheless, it is tempting to speculate that SPPL3 ap-
plies a different mechanism of substrate recognition than SPP, SPPL2a,
and SPPL2b and that SPPL3may be functionally more similar to rhom-
boid proteases.
In contrast to many conventional aspartic proteases, so far no con-
sensus cleavage site based on primary sequence elements within the
substrate has been described for GxGD aspartyl proteases. TMDs of
membrane proteins preferentially adopt an α-helical conﬁrmation
in which their peptide bonds are hardly accessible to proteases [93].
In order to make TMDs susceptible for intramembrane proteolysis it
was therefore postulated that their α-helical content needs to be
reduced by helix destabilizing amino acids [94]. Consistent with this
hypothesis, various signal peptides have been shown to contain
helix destabilizing amino acids within their h-region which critically
inﬂuence their proteolytic processing by SPP [44,47,69,95]. In addi-
tion, polar residues within the h-region of signal peptides may inﬂu-
ence cleavage by SPP, as for instance serine and cysteine residues
within the signal peptide of various HCV strains are critical for SPP
cleavage [44,47,95]. Whether these polar residues also simply affect
the helical content of the signal peptides or the hydroxyl or sulfhydryl
group in particular is required to trigger cleavage by SPP is not yet
fully understood. Similarly, cleavage of the Bri2 TMD by SPPL2b is
signiﬁcantly increased when the α-helical content of the Bri2 TMD
is reduced [96]. Interestingly, only one amino acid residue out of
four residues with a putative helix destabilizing potency signiﬁcantly
reduced the α-helical content of the Bri2 TMD in a phospholipid-
based environment [96]. This suggests that destabilisation of an
α-helical TMD is not simply caused by certain amino acid residues
but that rather context and position of these amino acids determine
their helix destabilizing potential and thus the accessibility of TMDs
to intramembrane proteolysis by SPP/SPPLs.
Although the length of a substrates ectodomain and the α-helical
content of its TMD are important determinants for the efﬁciency of pro-
cessing by SPP/SPPLs, these two properties of a substrate alone are not
sufﬁcient to trigger its processing. For instance, Bri3, which is a
close homologue of the SPPL2a/b substrate Bri2, does not undergo
intramembrane cleavage by SPPL2b, even if the ectodomain is artiﬁcial-
ly shortened and its TMD is replaced by that of Bri2 [88]. Bri2/Bri3 do-
main swapping analysis revealed that further determinants within the
juxtamembrane domains N- and C-terminal to the TMD are required in
addition to allow efﬁcient intramembrane proteolysis by SPPL2b [88].
In line with this charged residues in the juxtamembrane domain
C-terminal to the TMD of SPP substrates have been shown to interfere
with substrate processing [69].
Similar substrate determinants have been described earlier also
for the processing of γ-secretase substrates [97–99]. But in additionit has been discussed that substrate dimerization via GxxxGmotifs in-
ﬂuences substrate recognition and cleavage by γ-secretase [100].
Since a GxxxG motif within the Bri2 TMD does not affect its process-
ing by SPPL2b [96], this may suggest either that SPP/SPPLs and
γ-secretase differ fundamentally in this regard or that substrate
dimerization only inﬂuences the processing in certain enzyme–
substrate combinations.
To ﬁnally judge which substrate determinants are unique to indi-
vidual members or common to all members of the GxGD aspartyl pro-
tease family and whether certain enzyme–substrate combinations are
subject to a special regulation, further studies on newly identiﬁed
substrates, for instance on CD74, FasL, and FVenv as well as on so
far uncharacterized enzymes like SPPL3 or SPPL2c will be essential.
Nonetheless, one important conclusion that must be drawn from
the present results is that SPP/SPPLs have considerably higher sub-
strate speciﬁcity than initially thought [87] and are probably involved
in regulation of speciﬁc cellular pathways as well as in the degrada-
tion of selected membrane proteins.
4.3. Cleavage mechanism
Presently, only the cleavage mechanism applied by SPP and
SPPL2b has been investigated in more detail. SPPL2b utilizes multiple
cleavages within the TMD of TNFα to efﬁciently release TNFα ICD and
TNFα C-peptide (Fig. 5) from the cellular membrane [23]. While the
major cleavage event leading to the release of TNFα C-peptide takes
place in the C-terminal part of the TNFα TMD between Cys49 and
Leu50, the C-termini of the prevailing TNFα ICD species are Ser34,
Leu39 and Arg28 (Fig. 5) [23]. Neither ICDs with C-termini at Cys49
nor C-peptides with longer N-termini have been detected ([23] and
Fluhrer et al., unpublished data), suggesting that SPPL2b cleaves one
and the same TNFα molecule multiple times in a sequential manner
starting at Leu50 and terminating at Arg29. In addition to
C-peptides starting at Leu50, a minor fraction of C-peptides starting
at His52, Val55 or R60 have been identiﬁed ([23] and Fluhrer et al.,
unpublished data). This may indicate that substrate processing by
SPPL2b does not commence at one deﬁned position but rather in a
certain region within the substrate's TMD. Given that sequential
intramembrane proteolysis occurs periodically, the different starting
points of intramembrane proteolysis result in different product
lines. In line with this, minor amounts of TNFα ICDs terminating at
Ser37 and Cys30 have been detected using MALDI-TOF MS (Fluhrer
et al., unpublished data). Similar observations have been made for
substrate processing by γ-secretase [101–103]. In particular for
γ-secretase processing of βAPP two independent product lines have
been discussed, which result in Aβ species with variable neurotoxici-
ty [101,103]. Detergent-solubilized SPP cleaves synthetic peptides
based on the prolactin signal sequence mainly between Leu23 and
Leu24, resulting in ICD and C-peptide species with C- and N-termini,
respectively, that exactly match [104]. In addition a minor amount
of shorter ICD species, but interestingly no other C-peptide species
have been detected [104]. Whether these additional ICD species orig-
inate from a sequential cleavage catalysed by SPP or artiﬁcially result
from the detergent solubilisation remains to be elucidated.
Recently, palmitoylation of TNFα has been implicated in the sta-
bility of its N-terminal membrane bound fragment and is therefore
suggested to be necessary for an efﬁcient intramembrane cleavage
by SPPL2b [105]. The palmitoylation of Cys30 within the cytosolic
juxtamembrane of TNFα is discussed to be responsible for targeting
of TNFα to lipid rafts [106,107]. Since SPPL2b was also found to be
enriched in lipid rafts [15], co-localisation of substrate and enzyme
might favour intramembrane proteolysis in this particular lipid
microdomains [105]. So far it remains however unclear, whether sub-
strate acylation is a prerequisite for efﬁcient intramembrane proteol-
ysis by SPP/SPPL proteases in general or solely improves processing of
individual substrates by selected members of the SPP/SPPL family.
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Fig. 5. Cleavage sites identiﬁed in SPP/SPPLs substrates. So far, cleavage sites were only identiﬁed for SPP-mediated intramembrane proteolysis of the bovine prolactin (Prl) signal
peptide and for SPPL2b-mediated cleavage of TNFα. Membrane-spanning amino acid sequences are shown in one letter code, predicted TMD (TMHMM2.0) and signal peptide
(UniProt) regions are shown in italics. Black arrowheads, C-peptide species observed, grey arrowheads, ICD species identiﬁed, white arrowheads, signal peptidase cleavage sites,
*, C30 in TNFα is palmitoylated [106]. Large arrowheads indicate major cleavage products, small arrowheads indicate minor cleavage products. The luminal/extracellular space
is shaded in blue, while cytosol is shown in orange.
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tations within the conserved active site motifs [72,104,108]. While
mutation of the glycine residue next to the catalytically active aspar-
tate within the GxGD motif of SPP only affected the overall protease
activity [104], a similar mutation in SPPL2b additionally slowed the
sequential processing of TNFα and caused a relative increase of the
amounts of longer TNFα ICD species without signiﬁcantly affecting
the secretion of the respective TNFα C-peptide [108]. A similar muta-
tion within presenilin has been linked to familial Alzheimer's Disease
[109], since it increases the secretion of neurotoxic Aβ42 relative to
the less neurotoxic Aβ40 [2,110]. In this case the relative increase of
Aβ42 is intensiﬁed by a reduction of Aβ40 secretion [108], which
corresponds to the reduced ICD production from mutated SPP and
SPPL2b. To date only two more mutations known to increase Aβ42
in presenilin [111,112] have been transferred to SPP [104]. One of
these mutations reduced the processing of the synthetic prolactin sig-
nal peptide in vitro, while the other mutation had no effect [104].
Therefore, in order to clarify whether mutations within in conserved
regions of GxGD proteases similarly affect the cleavage mechanism
of all family members signiﬁcantly more mutations in different prote-
ases need to be investigated. Moreover, it cannot be excluded that the
same mutations within one SPP/SPPL protease differentially affect in-
dividual substrates.
SPP activity was shown to be inhibited by (Z-LL)2 ketone [10].
(Z-LL)2 ketonemimics the leucine-rich hydrophobic core of signal pep-
tides cleaved by SPP [10] and a derivative thereof was used to isolate
SPP from detergent solubilized ER membranes [4]. Based on this, it is
likely that (Z-LL)2 ketone directly targets the active site of SPP or inter-
acts with a potential substrate binding site in SPP. However, the formal
proof for this assumption is still missing. While in addition to SPP alsoSPPL2a and SPPL2b are inhibited by (Z-LL)2 ketone treatment
[23–25,60], γ-secretase activity is not blocked at similar concentrations
[113]. This is particularly interesting, as γ-secretase inhibitors
(GSIs), like L-685,458, which are known to target the active site
of γ-secretase [114,115], also reduce SPP and SPPL2a/b activity
[23,24,113]. This may imply that (Z-LL)2 ketone targets a site within
the active centre of SPP and SPPL2a/b which is structurally different
from that of presenilins while L-685,458 and other peptide-based
γ-secretase inhibitors seem to bind a structure in the active centre
common to γ-secretase, SPP and SPPL2a/b. Another γ-secretase inhib-
itor, N-[N-(3,5-diﬂuorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl
ester (DAPT) [116], which speciﬁcally targets the C-terminal fragment
of presenilin when incorporated within the high molecular weight
γ-secretase complex [117], only inhibits γ-secretase but fails to block
SPP and SPPL2b activity [25,113]. This indicates that the DAPT binding
site is unique to γ-secretase and not conserved within SPP and SPPL2b.
Besides GSIs which abolish the liberation of both cleavage prod-
ucts, so called γ-secretase modulators (GSM) have been shown to se-
lectively shift the sequential cleavage of γ-secretase substrates,
resulting in a changed pattern of secreted peptides for example of dif-
ferent Aβ species without alteration of the respective ICD species
(reviewed in [118]). First generation GSMs were based on the struc-
ture of certain non-steroidal anti-inﬂammatory drugs and shifted
the sequential cleavage of γ-secretase substrates in N-terminal direc-
tion [119]. Two such GSMs, sulindac sulﬁde and indomethacin, were
also shown to alter the cleavage site speciﬁcity of SPP within the
prolactin signal peptide in vitro, but only at high concentrations
[104]. But, in contrast to γ-secretase, the cleavage was shifted in
C-terminal direction [104]. Yet whether GSMs also inﬂuence the
cleavage site speciﬁcity of SPP in cellular model systems and in vivo
2837M. Voss et al. / Biochimica et Biophysica Acta 1828 (2013) 2828–2839and whether SPPL proteases are affected similarly remains to be
elucidated.
Helical peptides that mimic SPP substrates and thus potentially
target the initial substrate binding site (“docking site”) within SPP, in-
hibit both SPP and γ-secretase [120]. Photoafﬁnity labelling of SPP by
these helical peptides revealed a binding site distinct from that of
(Z-LL)2 ketone [120], suggesting that, as observed previously for
γ-secretase [121], the site of initial substrate binding to SPP is distinct
from the site of ﬁnal proteolysis. Moreover, binding of GSMs to SPP
did neither overlap with the binding of the helical peptides nor
with (Z-LL)2 ketone [120].
Based on the current knowledge about the homology of SPP/SPPL
proteases and the (Z-LL)2 ketone sensitivity of SPP and SPPL2a/b it
was expected that SPPL3 proteolytic activity is also blocked by
(Z-LL)2 ketone. Surprisingly, however, cleavage of FVenv by SPPL3 is
insensitive to active site-directed inhibitors such as (Z-LL)2 ketone
and to L-685,458 [70]. This ﬁnding may point to marked spatial differ-
ences between the active site architecture of and of other SPP/SPPL
family members. However, two studies analysing the cleavage of
synthetic peptides based on the prolactin signal sequence by
recombinantly expressed D. melanogaster SPPL3 [40] as well as the
SPPL3-mediated cleavage of a model substrate optimized for SPP
cleavage in a cell-based context [15], concluded that SPPL3 is sensi-
tive to such inhibitors. Contrary to these observations, a catalytically
inactive mutant of SPPL3 was not able to interact with those signal
peptide-based model substrates in a cellular context, while the corre-
sponding SPP mutant co-precipitated these substrates [57]. These dis-
crepancies may indicate that the effect of certain inhibitors on SPP/
SPPL proteases is dependent on the context applied in the respective
study. In line with this, a reporter construct based on a signal
sequence which is not cleaved by SPP in vitro [69] is cleaved by SPP
in a cellular context [71]. Therefore, additional studies using various
enzyme-substrate combinations and experimental conditions will
be required to ﬁnally answer the question whether inhibitors and
modulators affect the cleavage mechanism of all GxGD proteases in
a similar manner.
5. Outlook
Despite recent advances, we are just at the beginning of under-
standing the biochemical diversity and the biological signiﬁcance of
SPP/SPPL intramembrane proteases. A central issue will be to extend
and deﬁne the substrate spectrum of each individual protease. Based
on this, it can be anticipated that a more precise characterisation of
the substrate requirements of SPP/SPPLs as well as the molecular
mechanisms for substrate recognition and cleavage will be achieved.
For each of the already known or yet to be identiﬁed substrates, the
biological relevance of SPP/SPPL-mediated intramembrane proteoly-
sis may need to be evaluated individually, speciﬁcally related to the
question if their cleavage products fulﬁll any signalling function
after their liberation from the membrane. In this context the sug-
gested contribution of SPP/SPPL proteases to generalized membrane
protein turnover may be further assessed. In order to validate
biochemical in vitro ﬁndings and scrutinize the impact of these
proteolytic events in a complex organism, signiﬁcant advances can
be expected from in vivo studies using knockout mice. In particular,
these will be instrumental to further corroborate the speciﬁc role of
SPPL2a/b in immune regulation and inﬂammation and to evaluate
the suitability of certain SPP/SPPL proteases as therapeutic targets
for the treatment of malaria infections, the depletion of B cells in
autoimmune disorders or not yet recognised indications.
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